On April 30, 2026, the Brand Finance 2026 Global Pharmaceutical Brand Value Ranking was released. The report indicates that ten Chinese pharmaceutical companies have entered the global top 50, with a combined brand value of $12.09 billion.
The report includes authoritative rankings for the top 50 global pharmaceutical brands, the top 25 medical device brands, and the top 10 healthcare service brands. Among the listed Chinese companies, Sinopharm Group, as a leading enterprise, saw its brand value increase by 10.1% to $4.14 billion, maintaining its position at 11th globally. Sinopharm's Brand Strength Index rose by 3.6 points to 78, earning it the title of the strongest Chinese pharmaceutical brand. It ranked fifth globally in brand strength, with its rating upgraded from AA to AA+.
Guangzhou Pharmaceutical Holdings experienced significant growth, with its brand value surging 20.3% to $3 billion, making it the fastest-growing Chinese pharmaceutical brand on the list. It held steady at 15th place globally. As a longstanding traditional Chinese medicine brand, Guangzhou Pharmaceutical also increased its investment in digital marketing and social media, effectively enhancing its appeal to younger audiences and improving brand affinity.
Shanghai Pharmaceuticals saw a modest 1.7% rise in brand value to $1.55 billion, though its ranking dropped one spot to 20th globally. Yunnan Baiyao recorded a 9.9% year-on-year increase in brand value, reaching $1.01 billion and securing the 25th position worldwide. Its Brand Strength Index scored 77.8 points, ranking sixth among the world's strongest pharmaceutical brands.
CSPC Pharmaceutical Group and Pien Tze Huang were among the Chinese brands with the most significant ranking improvements on this year's list.
Globally, American and European pharmaceutical firms continued to dominate. Johnson & Johnson retained its position as the world's most valuable pharmaceutical brand, with a brand value of $17.71 billion. Its Brand Strength Index reached 82.4 points, maintaining a AAA- rating. Eli Lilly and Roche followed in second and third places, with brand values of $10.1 billion and $7.61 billion, respectively.
The President of Brand Finance China commented that the rise of Chinese pharmaceutical brands reflects not just value growth but a systematic improvement in brand strength ratings. He emphasized that this indicates leading Chinese pharmaceutical companies have transitioned from a phase of scale expansion to systematically building brand assets through technological innovation, international image shaping, cultural value mining, and precise brand positioning.
He further noted that to compete effectively in the global market, Chinese pharmaceutical brands must continue investing in innovation and translate these achievements into compelling brand narratives. Strengthening ESG communication and enhancing global brand reputation will be crucial for securing a more prominent position in the worldwide pharmaceutical brand landscape while better serving public health.
Comments